TH3RESA

NCT01419197 📎

Regimen

Experimental
T-DM1 3.6 mg/kg IV every 3 weeks until progression.
Control
Treatment of physician's choice (most commonly trastuzumab + chemotherapy).

Population

HER2-positive advanced breast cancer with progression after >= 2 prior HER2-directed regimens including trastuzumab and lapatinib plus a taxane.

Key finding

TH3RESA extended T-DM1's benefit to heavily pretreated HER2+ MBC, providing a later-line option for patients failing multiple HER2-directed regimens. Supported label expansion beyond 2L.

Source: PMID 24793816

Timeline

  • Publication: 2014 Jun

Guideline citations

  • NCCN BREAST